Biased agonism as a mechanism for differential signaling by chemokine receptors

Journal of Biological Chemistry

Volumn 288, Issue 49, 2013, Pages 35039-35048

  Rajagopal, Sudarshan ^a   Bassoni, Daniel L ^b   Campbell, James J ^c   Gerard, Norma P ^d   Gerard, Craig ^d   Wehrman, Tom S ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DiscoveRx Corporation   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARRESTINS; BIOLOGICAL SIGNALING; CHEMOKINE RECEPTORS; CHEMOKINES; DIFFERENTIAL SIGNALING; G PROTEIN;

BIOCHEMISTRY; BIOLOGY;

PEPTIDES;

BETA ARRESTIN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR5; GUANINE NUCLEOTIDE BINDING PROTEIN;

ARTICLE; BIASED AGONISM; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RESPONSE; EMBRYO; HUMAN; HUMAN CELL; INTERNALIZATION; LEUKOCYTE MIGRATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN TARGETING; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ARRESTIN; BIASED AGONISM; CHEMOKINES; G PROTEIN-COUPLED RECEPTORS (GPCR); G PROTEINS; SIGNALING;

ARRESTINS; CHEMOKINES; GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; KINETICS; LIGANDS; MODELS, BIOLOGICAL; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 84890282799     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.479113     Document Type: Article

References (35)

1. Schall, T. J., and Proudfoot, A. E. (2011) Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat. Rev. Immunol. 11, 355-363
2. Zlotnik, A., and Yoshie, O. (2012) The chemokine superfamily revisited. Immunity 36, 705-716
3. Power, C. A. (2003) Knock out models to dissect chemokine receptor function in vivo. J. Immunol. Methods 273, 73-82
4. Kenakin, T. (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol. Sci. 16, 232-238
5. Kenakin, T. (2007) Functional selectivity through protean and biased agonism: who steers the ship Mol. Pharmacol. 72, 1393-1401
6. Rajagopal, S., Rajagopal, K., and Lefkowitz, R. J. (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 9, 373-386
7. Boerrigter, G., Lark, M. W., Whalen, E. J., Soergel, D. G., Violin, J. D., and Burnett, J. C., Jr. (2011) Cardiorenal actions of TRV120027, a novel -arrestin- biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ. Heart Fail. 4, 770-778
8. Eglen, R. M. (2002) Enzyme fragment complementation: a flexible high throughput screening assay technology. Assay Drug Dev. Technol. 1, 97-104
9. Wehrman, T. S., Raab, W. J., Casipit, C. L., Doyonnas, R., Pomerantz, J. H., and Blau, H. M. (2006) A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc. Natl. Acad. Sci. U.S.A. 103, 19063-19068
10. Olson, K. R., and Eglen, R. M. (2007) -Galactosidase complementation: a cell-based luminescent assay platform for drug discovery. Assay Drug Dev. Technol. 5, 137-144
11. Bradley, J., and McLoughlin, D. (2009) Use of the DiscoveRx Hit hunter cAMPII assay for direct measurement of cAMP in Gs and Gi GPCRs. Methods Mol. Biol. 552, 171-179
12. Bassoni, D. L., Jafri, Q., Sastry, S., Mathrubutham, M., and Wehrman, T. S. (2012) Characterization of G-protein coupled receptor modulators using homogeneous cAMP assays. Methods Mol. Biol. 897, 171-180
13. Bassoni, D. L., Raab, W. J., Achacoso, P. L., Loh, C. Y., and Wehrman, T. S. (2012) Measurements of -arrestin recruitment to activated seven transmembrane receptors using enzyme complementation. Methods Mol. Biol. 897, 181-203
14. Hammer, M. M., Wehrman, T. S., and Blau, H. M. (2007) A novel enzyme complementation-based assay for monitoring G-protein-coupled receptor internalization. FASEB J. 21, 3827-3834
15. Rajagopal, S., Ahn, S., Rominger, D. H., Gowen-MacDonald, W., Lam, C. M., Dewire, S. M., Violin, J. D., and Lefkowitz, R. J. (2011) Quantifying ligand bias at seven-transmembrane receptors. Mol. Pharmacol. 80, 367-377
16. Furchgott, R. F. (1966) in Advances in Drug Research (Harper, N. J., and Simmonds, A. B., eds) pp 21-55, Academic Press, New York
17. Griffin, M. T., Figueroa, K. W., Liller, S., and Ehlert, F. J. (2007) Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o, Gs, and G15. J. Pharmacol. Exp. Ther. 321, 1193-1207
18. Ehlert, F. J. (2008) On the analysis of ligand-directed signaling at G protein- coupled receptors. Naunyn Schmiedebergs Arch. Pharmacol. 377, 549-577
19. Gregory, K. J., Hall, N. E., Tobin, A. B., Sexton, P. M., and Christopoulos, A. (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J. Biol. Chem. 285, 7459-7474
20. Meiser, A., Mueller, A., Wise, E. L., McDonagh, E. M., Petit, S. J., Saran, N., Clark, P. C., Williams, T. J., and Pease, J. E. (2008) The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. J. Immunol. 180, 6713-6724
21. Fong, A. M., Premont, R. T., Richardson, R. M., Yu, Y. R., Lefkowitz, R. J., and Patel, D. D. (2002) Defective lymphocyte chemotaxis in -arrestin2- and GRK6-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 99, 7478-7483
22. Gurwitz, D., Haring, R., Heldman, E., Fraser, C. M., Manor, D., and Fisher, A. (1994) Discrete activation of transduction pathways associated with acetylcholine m1 receptor by several muscarinic ligands. Eur. J. Pharmacol. 267, 21-31
23. Boerrigter, G., Soergel, D. G., Violin, J. D., Lark, M. W., and Burnett, J. C., Jr. (2012) TRV120027, a novel -arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ. Heart Fail. 5, 627-634
24. Gesty-Palmer, D., Flannery, P., Yuan, L., Corsino, L., Spurney, R., Lefkowitz, R. J., and Luttrell, L. M. (2009) A -arrestin biased agonist of a parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci. Transl. Med. 1, 1ra1
25. Whalen, E. J., Rajagopal, S., and Lefkowitz, R. J. (2011) Therapeutic potential of -arrestin- and G protein-biased agonists. Trends Mol. Med. 17, 126-139
26. Kohout, T. A., Nicholas, S. L., Perry, S. J., Reinhart, G., Junger, S., and Struthers, R. S. (2004) Differential desensitization, receptor phosphorylation, -arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor. J. Biol. Chem. 279, 23214-23222
27. Zidar, D. A., Violin, J. D., Whalen, E. J., and Lefkowitz, R. J. (2009) Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc. Natl. Acad. Sci. U.S.A. 106, 9649-9654
28. Drury, L. J., Ziarek, J. J., Gravel, S., Veldkamp, C. T., Takekoshi, T., Hwang, S. T., Heveker, N., Volkman, B. F., and Dwinell, M. B. (2011) Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc. Natl. Acad. Sci. U.S.A. 108, 17655-17660
29. Cox, M. A., Jenh, C. H., Gonsiorek, W., Fine, J., Narula, S. K., Zavodny, P. J., and Hipkin, R. W. (2001) Human interferon-inducible 10-kDa protein and human interferon-inducibleTcell- chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol. Pharmacol. 59, 707-715
30. Colvin, R. A., Campanella, G. S., Sun, J., and Luster, A. D. (2004) Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. J. Biol. Chem. 279, 30219-30227
31. Watts, A. O., Scholten, D. J., Heitman, L. H., Vischer, H. F., and Leurs, R. (2012) Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation. Biochem. Biophys. Res. Commun. 419, 412-418
32. Hu, S., Yang, K., Yang, J., Li, M., and Xiong, N. (2011) Critical roles of chemokine receptor CCR10 in regulating memory IgA responses in intestines. Proc. Natl. Acad. Sci. U.S.A. 108, E1035-E1044
33. Kahsai, A. W., Xiao, K., Rajagopal, S., Ahn, S., Shukla, A. K., Sun, J., Oas, T. G., and Lefkowitz, R. J. (2011) Multiple ligand-specific conformations of the -2-adrenergic receptor. Nat. Chem. Biol. 7, 692-700
34. Tsou, C. L., Peters, W., Si, Y., Slaymaker, S., Aslanian, A. M., Weisberg, S. P., Mack, M., and Charo, I. F. (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Investig. 117, 902-909
35. Mortier, A., Gouwy, M., Van Damme, J., and Proost, P. (2011) Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp. Cell Res. 317, 642-654